Bioequivalence evaluation of gliclazide 80 mg

Hypersensitivity to gliclazide, other sulphonylureas, sulphonamides or to any of the excipients. As the correlation was established the expected bioavailability of MR formulation can be accurately and precisely predicted from dissolution profile characteristics.

The dosage is therefore identical to that recommended for adults under the age of 65 years.

Article Information

The hair on the backside of the rats was removed with an electric hair clipper on the previous day of the experiment. Due to the presence of lactose, patients with rare hereditary problems of galactose intolerance, glucose galactose malabsorption, or the Lapp lactase deficiency should not take this medicinal product.

Adverse events were generally mild and transient, not requiring discontinuation of therapy. Diabetes mellitus is a metabolic disorder in which prolonged treatment is necessary.

The media compositions reflected those most commonly used for discriminatory dissolution methods and represent a biorelevant simulation of the stomach and small intestine conditions, where the majority of absorption of GLZ occurs. It is acknowledged that none animal model is identical to any human syndrome; none of the available animal models of type 2 diabetes mellitus exactly simulates the human type 2 diabetes mellitus.

After centrifugation — rpm for 10 minacetonitrile was added to the ethanol and the organic mixture was taken to near dryness by a steam of nitrogen at room temperature.

Methods Animal study Twenty four healthy Wistar rats were Weighing g selected for this study, all the animals were healthy during the period of the experiment.

Inclusion criteria included being within drawn during the study was Formulation and In-vitro, In-vivo evaluation of extender-release matrix tablet of zidovdine: The n5 - STZ model shows an unaltered basal hyperglycemia, glucose intolerance, raised glycosylated hemoglobin, a strong reduction 34 Phannacokinetics and Pharmacodynamics of GUclazide from Immediate Table 3.

Buffer solutions were prepared as described in USP. Mean gliclazide pharmacokinetic curves obtained on healthy and STZ-treated rats with treated MR formulation of gliclazide.

The study was performed under a single-dose, 2-treatment, 2-period, 2-sequence crossover design in a fasted condition with a washout period of 21 days. Therefore, in certain cases, especially for MR formulations, the dissolution test can serve as an indicator of in-vivo performance of a formulation.

The low solubility of GLZ has been described as the rate limiting step for drug dissolution and absorption, thus a prediction of its in vivo behavior based on a discriminative dissolution test should lead to a relevant in vitro—in vivo correlation IVIVC.

During controlled clinical trials in patients with type II diabetes, a modified release formulation of gliclazide 30 mg mgtaken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of HbA1c.

Study on the pharmacotherapy of Type 2 diabetes shows that neither IR nor MR gliclazide tablet is capable of providing the therapeutic levels of gliclazide.

Szilagyi A and Zrinyi M: Baker Bond C 18 colums J. The series of buffers consisted of HCl pH 1. A five-level calibration curve was prepared for each condition using concentrations of 2. Increased postprandial insulin and C-peptide secretion persists after two years of treatment.

As were as, the technological parameters like equipment, manufacturing process, batch size may be optimized. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. Introduction Diabetes mellitus is a major health problem and an important cause of prolonged ill health and early death 1.List of Marketing Authorisations (MA) containing Gliclazide registered and approved in Europe on cheri197.com Approved Marketing Authorisations (MA) containing Gliclazide in Europe.

40 cpr div 80 mg. Approval Date. Brand Name. Gliclazide. Application Number. Packaging Presentation. Regulatory Information.

Antidiabetic Agents, Sulfonylurea (Systemic)

metabolites are necessary for the evaluation of pharmacokinetics (PK), bioavailability (BA) and bioequivalence (BE) studies [10].

A simple, sensitive HPLC method was developed for studying the pharmacokinetics of gliclazide in rabbit model. Maintenance: Oral, to 20 mg a day, of which doses up to 10 mg are usually taken as a single dose with breakfast or the first main meal, while doses over 10. Formulation and evaluation of gliclazide loaded liposomes M.

P. Subash Chandran* and V. P. Pandey Department of Pharmacy, Annamalai University, Annamalai nagar, Chidambaram, T.N. _____ ABSTRACT Diabetes is the disease caused due to deficiency of insulin. Antidiabetic drug Gliclazide decreases blood glucose level by inducing insulin. Drug Approvals by the Medicines Control Council in South Africa containing Gliclazide.

Original Data: South African Medicines Price Registr Bioequivalence / Clinical / Pre-Clinical Testing; Austell Gliclazide 80 mg. Application Number. Packaging Presentation.

Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations

The safety of a modified release formulation of gliclazide (30 mg mg) has been evaluated in controlled clinical trials in patients, of which patients were treated in long-term comparative trials against a gliclazide immediate release formulation (80 mg mg), for up to ten months.

Download
Bioequivalence evaluation of gliclazide 80 mg
Rated 0/5 based on 28 review